Compare PDSB & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDSB | JSPR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5M | 43.7M |
| IPO Year | N/A | N/A |
| Metric | PDSB | JSPR |
|---|---|---|
| Price | $0.96 | $1.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $9.00 | ★ $18.13 |
| AVG Volume (30 Days) | 686.2K | ★ 1.1M |
| Earning Date | 11-13-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $1.39 |
| 52 Week High | $2.20 | $7.19 |
| Indicator | PDSB | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 41.71 |
| Support Level | $0.92 | $1.48 |
| Resistance Level | $1.02 | $1.68 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 51.06 | 21.21 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.